These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11569237)

  • 1. [Dalphaz-retard treatment of urination disorders in men and women].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2001; (4):47-8. PubMed ID: 11569237
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
    Sciarra A
    Eur Urol; 2007 Jun; 51(6):1485-7. PubMed ID: 17275984
    [No Abstract]   [Full Text] [Related]  

  • 4. Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
    Armitage JN; Emberton M
    BJU Int; 2006 Mar; 97(3):439-41. PubMed ID: 16469003
    [No Abstract]   [Full Text] [Related]  

  • 5. A current review of medical therapy for benign prostatic hyperplasia.
    Brown GA; Sussman DO
    J Am Osteopath Assoc; 2004 Feb; 104(2 Suppl 2):S11-6. PubMed ID: 15038398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The objective of medical treatment: relieve the symptoms or stop the course?].
    Desgrandchamps F
    Ann Urol (Paris); 2006 Mar; 40 Spec No 1():14-6. PubMed ID: 16649585
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The place of pharmacologic treatment in benign prostatic hyperplasia.
    Caine M
    Semin Urol; 1985 Nov; 3(4):311-6. PubMed ID: 2441447
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of alpha1-adrenoceptors on prostate cancer growth.
    Stamatiou K; Skolarikos A; Sofras F
    Urology; 2008 Apr; 71(4):756-7. PubMed ID: 18291511
    [No Abstract]   [Full Text] [Related]  

  • 12. Breakthrough treatment for prostate enlargement.
    Johns Hopkins Med Lett Health After 50; 2003 Apr; 15(2):3, 7. PubMed ID: 12712965
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
    Crawford ED
    BJU Int; 2005 Jun; 95 Suppl 4():1-5. PubMed ID: 15871729
    [No Abstract]   [Full Text] [Related]  

  • 14. [The experience in postoperative administration of alpha-adrenoblockers].
    Miller AM
    Urologiia; 2007; (5):55-8. PubMed ID: 18254227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
    Seftel A
    J Urol; 2005 Nov; 174(5):1940-1. PubMed ID: 16217354
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function.
    Kaplan SA
    Urology; 2004 Mar; 63(3):428-34. PubMed ID: 15028431
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
    Fine SR; Ginsberg P
    J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
    Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
    Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.